Literature DB >> 21429802

The pharmacokinetics and pharmacodynamics of rifampicin in adults and children in relation to the dosage recommended for children.

P R Donald1, J S Maritz, A H Diacon.   

Abstract

The dosages of antituberculosis agents recommended for treatment of childhood tuberculosis often reflect those for adult patients with similar mg/kg body weight dosages and ranges advised. Literature relating to the pharmacokinetics and pharmacodynamics of rifampicin (RMP) is reviewed and the serum concentrations reached by adults, both patients and healthy volunteers and children, established or not established on RMP, compared. Straight line regression of maximum RMP serum concentrations (C(max)) on dosage, weighted for the number of individuals, found slopes (SE) of 1.025 (0.067) and 0.881 (0.046) respectively for adult volunteers not established and established on RMP (P = 0.076), and similarly 0.748 (0.057) and 0.684 (0.038) respectively for adult patients (P < 0.001) and 0.622 (0.050) and 0.368 (0.041) respectively for children (P < 0.001). These results indicate that for equivalent RMP dosages adult patients reach a lower C(max) than adult volunteers and that adults, both volunteers and patients established on RMP reach higher C(max) values than children; children established on RMP require approximately twice the mg/kg body weight dosage of RMP to reach serum concentrations equivalent to those of adults. It is noteworthy that many adult patients receiving currently recommended RMP dosages also do not reach the often recommended RMP 2 h serum concentration of 8 μg/mL.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21429802     DOI: 10.1016/j.tube.2011.02.004

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  18 in total

1.  Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children.

Authors:  Hongmei Yang; Anthony Enimil; Fizza S Gillani; Sampson Antwi; Albert Dompreh; Antoinette Ortsin; Eugene Adu Awhireng; Maxwell Owusu; Lubbe Wiesner; Charles A Peloquin; Awewura Kwara
Journal:  Pediatr Infect Dis J       Date:  2018-01       Impact factor: 2.129

Review 2.  Paediatric pharmacokinetics: key considerations.

Authors:  Hannah Katharine Batchelor; John Francis Marriott
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

3.  Evaluation of the Adequacy of WHO Revised Dosages of the First-Line Antituberculosis Drugs in Children with Tuberculosis Using Population Pharmacokinetic Modeling and Simulations.

Authors:  Yasuhiro Horita; Abdullah Alsultan; Awewura Kwara; Sampson Antwi; Antony Enimil; Antoinette Ortsin; Albert Dompreh; Hongmei Yang; Lubbe Wiesner; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

4.  Effect of Diabetes Mellitus on the Pharmacokinetics and Pharmacodynamics of Tuberculosis Treatment.

Authors:  Omamah Alfarisi; Vidya Mave; Sanjay Gaikwad; Tushar Sahasrabudhe; Geetha Ramachandran; Hemanth Kumar; Nikhil Gupte; Vandana Kulkarni; Sona Deshmukh; Sachin Atre; Swapnil Raskar; Rahul Lokhande; Madhusudan Barthwal; Arjun Kakrani; Sandy Chon; Amita Gupta; Jonathan E Golub; Kelly E Dooley
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

Review 5.  Tuberculous Meningitis in Children and Adults: New Insights for an Ancient Foe.

Authors:  Alyssa Mezochow; Kiran Thakur; Christopher Vinnard
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09-20       Impact factor: 5.081

6.  Assessment of juvenile pigs to serve as human pediatric surrogates for preclinical formulation pharmacokinetic testing.

Authors:  Wyatt J Roth; Candice B Kissinger; Robyn R McCain; Bruce R Cooper; Jeremy N Marchant-Forde; Rachel C Vreeman; Sophia Hannou; Gregory T Knipp
Journal:  AAPS J       Date:  2013-04-18       Impact factor: 4.009

7.  Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes.

Authors:  H McIlleron; H Hundt; W Smythe; A Bekker; J Winckler; L van der Laan; P Smith; H J Zar; A C Hesseling; G Maartens; L Wiesner; A van Rie
Journal:  Int J Tuberc Lung Dis       Date:  2016-07       Impact factor: 2.373

8.  Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.

Authors:  A Bekker; H S Schaaf; H R Draper; L van der Laan; S Murray; L Wiesner; P R Donald; H M McIlleron; A C Hesseling
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

9.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

10.  A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children.

Authors:  Alessandro Schipani; Henry Pertinez; Rachel Mlota; Elizabeth Molyneux; Nuria Lopez; Fraction K Dzinjalamala; Joep J van Oosterhout; Steve A Ward; Saye Khoo; Gerry Davies
Journal:  Br J Clin Pharmacol       Date:  2016-01-30       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.